WO1993018153A1 - Vaccinia virus b15r used in interleukin b1-involving condition - Google Patents
Vaccinia virus b15r used in interleukin b1-involving condition Download PDFInfo
- Publication number
- WO1993018153A1 WO1993018153A1 PCT/GB1993/000460 GB9300460W WO9318153A1 WO 1993018153 A1 WO1993018153 A1 WO 1993018153A1 GB 9300460 W GB9300460 W GB 9300460W WO 9318153 A1 WO9318153 A1 WO 9318153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- interleukin
- receptor
- binding
- vaccinia virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to vaccinia virus proteins, uses and products relating thereto.
- IL-1 ⁇ receptor is used in the text as referring to the vaccinia virus B15R polypeptide or allele or functionally equivalent fragment, derivative or variant thereof, the word "receptor" should be
- VV Vaccinia virus
- the linear double-stranded genome of approximately 185,000 base pairs has the potential to encode at least 200 proteins (Moss, B.
- vaccinia virus encodes many enzymes and protein factors necessary for transcription and replication of its genome.
- the virus also encodes a variety of factors which modulate virus replication in the multicellular host and aid evasion of the host immune system (Moss, B. (1990a)).
- Advances in molecular genetics have made possible the construction of recombinant vaccinia viruses that contain and express genes derived from other
- the recombinant viruses retain their infectivity and express the foreign gene (or genes) during the normal replicative cycle of the virus. Immunisation of animals with the recombinant viruses has resulted in specific immune responses against the protein(s) expressed by the vaccinia virus, including those protein(s) expressed by the foreign gene(s) and in several cases has conferred protection against the pathogenic organism from which the foreign gene was derived.
- Recombinant vaccinia viruses have, therefore, potential application as new live vaccines in human or veterinary medicine.
- Advantages of this type of new vaccine include the low cost of vaccine manufacture and administration (because the virus is self-replicating), the induction of both humoral and cell-mediated immune responses, the stability of the viral vaccine without refrigeration and the practicality of inserting multiple foreign genes from different organisms into vaccinia virus, to construct polyvalent vaccines effective against multiple pathogens.
- a disadvantage of this approach is the use of a virus vaccine that has been recognised as causing rare vaccine-related complications.
- Vaccinia virus contains two genes designated B15R and B18R from near the right inverted terminal repeat (ITR) which are each predicted to encode a soluble glycoprotein that has three immunoglobulin-like (Ig) domains, but no transmembrane anchor sequence of
- the product of B18R is apparently expressed on the surface of the infected cell early during infection and antibodies directed against a mixture of it and other proteins confer resistance to virus infection without directly neutralizing infectivity (Ueda, Y., Morikawa, S. and Matsuura, Y. (1990); Ueda and Tagaya, I. (1973) J. Exp. Med. 138, 1033-1043; Ikuta, K., Miyamoto, H. and Kato, S. (1980).
- IL interleukin
- gene product B18R does not bind interleukin-1 (IL-1) or interleukin-6 (IL-6).
- IL-6 interleukin-6
- gene product B15R does bind IL-1, though not IL-6.
- this binding is specific for IL- ⁇ as IL- ⁇ and the IL-1 receptor antagonist protein (IL-1ra) do not bind to the B15R gene product.
- one or more of the gene sequences B15R and B18R may be inactivated, or part or all of one or more of these gene sequences may be deleted from the viral genome to allow (i) greater attenuation of the virus; and/or (ii) enhancement of immunogenicity of recombinant vaccinia virus; and/or (iii) further gene sequences insertion sites, so that more foreign DNA may be included in the virus.
- Inactivation of the gene sequences may be by mutation or the insertion of foreign DNA.
- one or more of the gene sequences B15R and B18R may be changed to alter the function of a protein product encoded by the nucleotide sequence.
- Mutation of the nucleotide sequence may be effected by the deletion, addition, substitution or inversion of one or more nucleotides.
- DNA sequences encoding one or more heterologous polypeptides may be incorporated in the viral genome.
- the DNA sequences encoding the heterologous peptides may be inserted into one or more ligation sites created by the deletion or deletions from the viral genome.
- a heterologous peptide is one not normally coded for by wild type vaccinia virus.
- the heterologous nucleotide sequence will encode an immunogen or a
- polypeptide will be substantially homologous to an epitope expressed by a pathogenic organism during
- the recombinant vaccinia viruses as described have the potential for enhanced immunogenicity. This may result from the deletion of vaccinia genes B15R and/or B18R which cause immunosuppression.
- the recombinant vaccinia vectors as described may be used as immunogens for the production of monoclonal and polyclonal antibodies or T-cells with specificity for heterologous peptides encoded by DNA sequences ligated into the viral genome.
- the term antibody as used above should be construed as also covering antibody fragments and derivatives of a parent antibody and which have the same specificity as the parent antibody.
- the monoclonal antibodies, polyclonal antibodies, antisera and/or T-cells produced by the use of the recombinant virus vectors hereof can be used in the diagnostic tests and procedures, for example, in
- detecting antigen in a clinical sample can also be used therapeutically or prophylactically for
- Diagnostic test kits may comprise monoclonal
- antibodies, polyclonal antibodies, antisera and/or T-cells obtained by the use of the recombinant vaccinia vectors described.
- Vaccines and medicaments may comprise a recombinant vaccinia virus as described. These may have enhanced safety and immunogenicity over current vaccinia virus strains for the reasons indicated.
- a method of attenuating a vaccinia virus vector may comprise: a) deleting part or all of one or more of the following nucleotide sequences from the viral genome; and/or b) inactivating one or more of said nucleotide sequences by mutating said nucleotide sequences or by inserting foreign DNA; and/or c) changing said one or more nucleotide sequences to alter the function of a protein product encoded by said nucleotide sequence;
- nucleotide sequences are sequences designated herein as: i) B15R, ii) B18R.
- a vaccinia virus vector as described may be used to prepare a vaccine or a medicament.
- the translation products encoded by the nucleotide sequences B15R and B18R may have pharmaceutical utility. In particular, they may have utility as anti-inflammatory medicaments.
- genes and/or translation products thereof may be used in processes relating to the preparation of an anti-inflammatory medicament.
- the gene product B15R binds IL-l, though not IL-6.
- this binding is specific for IL-1 ⁇ as IL-1 ⁇ and IL-lra do not bind to the B15R gene product.
- IL-1 ⁇ is the IL-1 form which is released by the cell and acts on other"cell types in pathological situations (Dinarello, C.A., & Wolff S.M., 1993 New Eng. J. Med. vol.328 p106-113).
- IL-1 ⁇ is implicated in chromic inflammatory conditions such as rheumatoid arthritis and it has the following functions in relation to inflammation: i) it acts as a T-cell activator; ii) it induces fibroblast proliferation; iii) it increases the production of mediators of the
- fibroblasts and iv) it increases the production of collagenase from chondrocytes (Digiovine F.S. et al, 1990, Immunol. Today Vol.11 p13-20). Therefore the gene product of B15R which can bind to IL-1 ⁇ provides a means of blocking the activity of IL-1 ⁇ in order to control and/or reduce the symptoms of inflammation.
- IL-1 ⁇ acts as a mediator in septic shock and it is a growth factor for certain malignant cells e.g. leukaemic cells. Therefore the gene product of B15R provides a means for controlling septic shock and growth of certain tumour cells.
- IL-1 ⁇ receptor may be used to control disease mediated by excessive fever.
- the present invention provides use of the nucleotide sequence designated herein as B15R, or of a nucleotide sequence coding for an allele of, or
- a polypeptide which is encoded by the nucleotide sequence designated herein as B15R or of an allele of, or functionally equivalent fragment, derivative or variant of the polypeptide, to manufacture a medicament for the treatment of a condition in which IL-1 ⁇ is involved in the mediation of one or more symptoms associated with the condition.
- An allele of, or functionally equivalent fragment, derivative or variant of the B15R polypeptide may be any polypeptide with substantial homology to part or all of the B15R polypeptide and which also has the ability to bind IL-1 ⁇ .
- Conditions may be fever, inflammation, diseases such as rheumatoid arthritis in which inflammation is
- cytokine IL-1 ⁇ is the primary mediator of fever.
- the present invention particularly provides use of the nucleotide sequence designated herein as B15R, or a nucleotide sequence coding for an allele of, or functionally
- polypeptide encoded by the B15R nucleotide sequence in a process relating to the manufacture of a medicament for the treatment of fever. Also provided is use of a polypeptide encoded by the nucleotide sequence designated herein as B15R or of an allele of, or functionally equivalent fragment, derivative or variant of the
- polypeptide to manufacture such a medicament is also provided.
- a pharmaceutical which is an anti-fever medicament is also provided.
- a pharmaceutical which is an anti-fever medicament comprising a polypeptide which is encoded by the nucleotide sequence designated herein as B15R, or an allele of, or functionally equivalent fragment derivative or variant of the polypeptide.
- a diagnostic reagent for the detection or measurement of interleukin-1 ⁇ in a sample which reagent comprises a polypeptide encoded by the nucleotide sequence designated herein as B15R, or of an allele of, or functionally equivalent fragment,
- a diagnostic kit which comprises a diagnostic reagent as described above and one or more ancillary kit
- the proteins may be produced in a recombinant system according to techniques well known in the art.
- the nucleotide sequences provided herein could be inserted into a suitable expression vector (not necessarily vaccinia, for example the baculovirus system described herein).
- a suitable expression vector not necessarily vaccinia, for example the baculovirus system described herein.
- Such vectors can then be used to infect or transform a cell line suitable for the production of these particular proteins.
- Reagents comprising polypeptides such as the B15R gene product, or alleles of or functionally equivalent fragments, derivatives or variants of that gene product may be used as research tools as a means to study the function of IL-1 ⁇ versus IL-1 ⁇ .
- FIG. 1(A) HindIII restriction map of the 186kb W genome.
- the 9.8kb SalI I fragment is expanded to show the position and direction of transcription of the genes B15R and B18R and the serpin genes (Smith, G.L., Howard, S.T. and Chan, Y.S. (1989). J. Gen. Virol. 70, 2333-2343) (this nomenclature indicates the genes are the fifteenth and eighteenth ORFs starting from the left end of the HindIII B and are transcribed rightwards towards the genomic terminus).
- Figure 1(B) Nucleotide sequence and deduced amino acid sequence of gene B15R. Potential transcriptional control signals are underlined and a possible signal peptide at the N-terminus is boxed. Sites for the addition of N-linked carbohydrate (NXS/T) are boxed and the cys residues likely to form disulphide bonds within Ig-like domains are stippled.
- NXS/T N-linked carbohydrate
- Figure 1(C) Nucleotide sequence and deduced amino acid sequence of gene B18R. The three amino acid
- FIG. 1 Amino acid alignment of the Ig domains from B15R and B18R with the Ig-like domains of the human and murine IL-1RI, the human IL-6R, the VV haemagglutinin (VV HA), domain 1 of the fasciclin II, domain 3 of myelin-associated glycoprotein and the V-domain of Ig kappa.
- the regions predicted to form the ⁇ -strand structures of Ig-like domains are indicated above the alignment. Residues identical in 6 or more sequences are boxed. A few residues between the ⁇ -strands B and C have been omitted. Also omitted for brevity are ⁇ -strands D and, where appropriate, C' and C". Higher numbers of residues (about 30 or more) between strands C and E are indicative of the V domains.
- FIG. 4 S1 Mapping of 5' Ends of mRNAs Coding for B15R and B18R.
- Specific 5' radiolabeled probes (lane P), prepared as described in Experimental Procedures, were hybridized with yeast transfer RNA (lane 1) or vaccinia virus early (lane 2) or late (lane 3) RNA and digested with SI nuclease. Nuclease-resistant fragments were resolved on a sequencing gel alongside an M13 sequencing ladder (lanes A,C,G and T). Autoradiographs
- B15R (A) and B18R (B) probes are shown. The sizes of the probes and fragments protected are indicated in bases. Indicated below the autoradiographs are the probe position relative to the ORFs (underline and asterisks), the nucleotide and the deduced amino acid sequence at the 5' end of the ORFs, the vaccinia late promoter consensus sequence (underline), and the sites of transcriptional initiation (asterisks).
- FIG. 1 Structure of Recombinant Vaccinia Virus Genomes.
- Vaccinia virus DNA was digested with HindIII (A) or ClaI (B), and fragments were resolved on an agarose gel and transferred to nitrocellulose. Filters were probed with fragments containing the gene and flanking sequences of B15R (lane a) or B18R (lane b), with an internal oligonucleotide to B15R (lane c) or an internal fragment to B18R (lane d). Sizes in kilobases are indicated. Schematic representations of the
- HindIII (H) or Clal (C) fragments containing the TK gene hatchched box
- B15R gene shading box
- B18R gene closed box
- B15R from vaccinia virus-infected cells.
- BS-C-l cells were mock infected (M) or infected with WR, vB15R, or v B15R and pulse-labeled with 35 STrans-label either from 2 to 4hr after infection in the presence of cytosine arabinoside (E) or from 6 to 8 hr after infection in the absence (L) or presence (T) of tunicamycin.
- E cytosine arabinoside
- T tunicamycin
- B Identification of B18R from vaccinia virus-infected cells.
- BS-C-l cells were infected with vB18R or v B18R and pulse-labeled with 35 STrans-label from 6 to 8h after infection, the cell extracts and media were
- (C) Expression of B15R and B18R in baculovirus-infected insects cells Sf cells infected with AcNPV, AcB15R, or AcB18R were pulse-labeled with 35 STrans-label for 2 hr after 24 hr of infection. Proteins present in cells and media were analyzed by SDS-PAGE and visualized by autoradiography. As in (A), the quantity of sample from medium was estimated to correspond to about four times the amount analyzed from cells.
- the B15R (open arrowhead) and B18R (closed arrowhead) gene products and the molecular size markers are indicated in kilodaltons. The positions of ⁇ -galactosidase ( ⁇ gal), coexpressed with B15R and B18R in the recombinant baculoviruses, and polyhedrin (P), expressed only. in AcNPV, are shown.
- Figure 7 Binding Assays to IL-1 ⁇ , IL-1 ⁇ and IL-6.
- EL4 6.1 C10 cells, U266 cells, mock- or vaccinia (WR)-infected TK-143 cells, and Sf cells infected with AcNPV, AcB15R, or AcB18R were dotted onto nitrocellulose
- IL-1 ⁇ 120 pM
- IL-1 ⁇ 200 pM
- IL-6 IL-6
- FIG. 8 Binding Assay in Solution to Recombinant Viruses.
- Binding is expressed as a
- the percentages refer to the binding in the absence of competitor, which was 3720 cpm for 125 I-IL-1 ⁇ and EL4 6.1 C10 cells (A), 2040 cpm for 125 I-IL-1 ⁇ and EL4 6.1 C10 cells (B), and 4963 cpm for 125 I-IL-6 and U266 cells (C).
- mice Groups of five mice were intransally infected with 3 ⁇ 10 7 (panels a), 10 7 (panels b), 10 6 (panels c), 10 5 (panels d) or 10 4 (panels e) pfu of WR (open circle) or v B15R (closed circle) and examined daily for symptoms of illness or death. The number of animals that
- mice were intransally infected with 10 5 (panels a) of 10 4 (panels b) pfu of WR (open circle) or v B15R (closed circle). Symptoms of illness were scored from zero to four, and the mean value of each group was represented. Animals were weighed individually each day and the mean group weight was expressed as the percentage of the mean weight of that group of animals immediately prior to infection. No mortalities occurred at these doses of virus.
- FIG. 12 Effect of Expression of the Vaccinia IL-1 ⁇ Receptor on Mice Infected with Vaccinia Virus.
- a representative mouse 5 days after infection with 10 5 pfu of WR (a) or v B15R (b) is shown. Note the ruffled fur in (b), which correlated with accelerated weight loss (see Figure 8B, panels a).
- Cowpox Tissue culture medium (1 ⁇ 10 5 cell equivalents) from TK-143 cells infected with the indicated viruses was incubated in a binding assay in solution with 100 pM of radioiodinated IL-1 ⁇ or mIL-1 ⁇ , expressed in femtomoles, is shown.
- One femtomole corresponded to 935 or 535 cpm for IL-1 ⁇ or mIL-1 ⁇ , respectively.
- FIG. 14 Kinetics of symptoms of illness and mortality in mice infected with recombinant vaccinia viruses.
- BALB/c mice were intranasally infected with WR, v B15R or v B18R as described in Table 2.
- recombinants were examined for illness and the number of animals with symptoms (including mortality) in each group were represented as a function of time. Symptoms scored were (a) possession of ruffled fur (b) hunching and (c) immobility.
- the nucleotide sequence of the SalI I restriction fragment of the vaccinia virus genome were determined by established methods (Sanger, F. et al.
- the 9.8kb SalI I fragment of vaccinia virus was isolated from cosmid 6, which contains virus DNA derived from a rifampicin resistant mutant (Baldick, C..J. & Moss, B. (1987) Virology 156, 138-145), and was cloned into SalI cut pUC13 to form plasmid pSalI I.
- the SalI fragment was separated from plasmid sequences and self-ligated with T4 DNA ligase.
- Circular molecules were randomly sheared by sonication, end-repaired with T4 DNA polymerase and Klenow enzyme, and fragments of greater than 300 nucleotides cloned into SmaI cut M13mp18. Single stranded DNA was prepared and sequenced using the dideoxynucleotide chain termination method (Sanger, F., Nicklen, S. & Coulson, A.R. (1977) Proc. Natl. Acad. Sci. USA. 74, 5463-5467), using
- IL-1 a cytokine produced in response to infection and tissue injury, is involved in the regulation of the inflammatory and immune responses and in the activation of a broad spectrum of systemic effects that contribute to host defense (Dinarello 1988, 1989; Di Giovine and Duff 1990).
- the two forms of IL-1, IL-1 ⁇ and IL-1 ⁇ produce similar biological effects that are mediated by interaction with specific receptors in different cells.
- IL-1 receptors There are two classes of IL-1 receptors, and both bind IL-1 ⁇ and IL-1 ⁇ with similar affinities (Dower, S.K., and Urdal, D.L. (1987)).
- the 80 kDa type I IL-1 receptor is found on T cells and fibroblasts (Bird, T.A., and Saklatvala, J. (1986) Nature 324, 263-266), while the 60 kDa type II IL-1 receptor is present in B cells and macrophages (Matsushima, K. et al (1986) J. Immunol. 136, 4496-4508).
- IL-1ra IL-1 receptor antagonist
- Genes B15R and B18R (Figure 1) from near the right hand inverted terminal repeat ( ITR) are predicted to encode proteins of 36.5 kDa and 40.7 kDa, respectively, that have an N-terminal hydrophobic sequence, possible attachment sites for N-linked carbohydrate and
- the nucleotide sequence and deduced amino acid sequence around the gene designated B15R is shown in figure IB.
- the nucleotide sequence shown is 11462-12664 nucleotides from the left end of the vaccinia virus HindIII B fragment and the coding region for B15R is at nucleotide positions 11584-12561 (or at nucleotides 815 to 1792 from the left end of the SalI I fragment).
- nucleotide sequence and deduced amino acid sequence around the gene designated B18R is shown in figure 1c.
- the nucleotide sequence shown is 15448-16741 nucleotides from the left end of the vaccinia virus
- HindIII B fragment and the coding region for B18R is at nucleotide positions 15568-16621 (or at nucleotides 4799 to 5851 from the left end of the SalI I fragment).
- the single letter code is used for the designation of amino acids.
- B15R and B18R each possess three domains with characteristics of the immunoglobulin (Ig) superfamily (Williams, A.F. and Barclay, A.N. (1988). Ann. Rev.
- B15R and the external region of IL-1Rs have a very similar length.
- a glycosylation site is conserved in domain 1, ⁇ -strand F of IL-1Rs and B15R despite divergence of amino acid sequence.
- (6) Domain 3 does not contain additional cysteines and is longer than 1 and 2 in B15R, B18R and the IL-1Rs.
- VV proteins are related to each other (22.5% identity), to the human and murine IL-1R, the human IL-6R (Yamasaki, K., Taga, T., Hirat, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T. and Kishismoto, T. (1988).
- Ig immunoglobulin
- VV haemagglutinin is another member of this superfamily (Jin, D., Li, Z., Jin, Q., Yuwen, H. and Hou, Y. (1989). J. Exp. Med. 170, 571-576).
- the B18R sequence from VV strain IHD was recently
- VV may be combatting this part of the immune response by producing proteins which mimic the receptors for IL-1 and IL-6.
- B15R and B18R ORFs are actively transcribed, translated, and secreted to the medium during the vaccinia virus replication cycle.
- the B15R gene product is shown to bind IL-1 ⁇ when expressed from vaccinia or from recombinant baculovirus.
- the role of the IL-1 ⁇ binding activity in the biology of vaccinia virus was investigated by deleting the gene from the virus genome and analyzing the biological effects on infected mice. The biological effects on infected mice were also investigated for vaccinia virus without the B18R coding sequence. The presence of the binding activity in other orthopoxviruses is also presented.
- the cell line EL4 6.1 C10 a subclone of the mouse thymoma EL4 that expresses a high number of IL-1 binding sites (MacDonald et al, 1985), was a gift of H.R.
- Sf 21 insect cells and AcNPV were obtained from R. Possee (Natural Environmental Research Council Institute of Virology and Environmental Microbiology, Oxford) and were cultured in TC100 medium (GIBCO) containing 10% fetal calf serum (Brown and Faulkner, 1977).
- Vaccinia virus strain WR and recombinants derived from it were grown in CV-1 or BS-C-1 cells. TK-143 and HeLa D98 cells were used for the selection of
- the WR strain was obtained from B. Moss (National Institute of Health, Bethesda, Maryland) and cells were obtained from the American Type Culture
- Copenhagen strain were obtained from J. Zhou (Princess Alexandra Hospital, Brisbane, Australia) and R. Drillien (University Louis Pasteur, France),
- Radioiodinated human recombinant IL-6 was purchased from Amersham. IL-1 ⁇ had been, radioiodinated using the chloramine-T procedure to a specific activity of 70-120 ⁇ Ci/ ⁇ g. IL-1 ⁇ and IL-6 had been labeled with Bolton Hunter reagent to a specific activity of 80-180 ⁇ Ci/ ⁇ g and 800-1200 Ci/mmol, respectively. Unlabeled human recombinant IL-1 ⁇ (code 86/632), IL-1 ⁇ (code 86/680), and IL-6 (code 88/514) were obtained from the National
- IL-1 ⁇ and IL-1 ⁇ were 10 5 U/ ⁇ g and for IL-6 was 5 ⁇ 10 3 U/ ⁇ g.
- Unlabeled human recombinant IL-IRA specific activity 1 ⁇ 10 5 to 1.4 ⁇ 10 5 U/mg, was purchased from British Biotechnology.
- a derivative of plasmid pUC118 (Vieira and Messing, 1987) was constructed that contained the entire B15R ORF, lacking most of the flanking regions, and with convenient restriction sites at each end. A combination of subcloning and PCR was used. The left end SalI-XbaI fragment of the SalI I fragment of vaccinia DNA
- pAA1 containing B15R was inserted into SalI- and BamHI-cut pUC118, and the resultant plasmid was called pAA1.
- pAA1 was digested with EcoRV and XbaI, and the largest fragment was gel purified, end filled with Klenow fragment, and self-ligated to form pAA3, which contains 348 bp of the 3' flanking region.
- oligonucleotide that hybridizes to an internal sequence of B15R, corresponding to nucleotides 1008-1025 of the SalI I fragment (B15R-2; 5'-CCGCTCCTCGTTTTTCCC-3').
- the fourth nucleotide of B15R in the PCR fragment was G instead of A to create a NcoI recognition sequence, giving rise to a serine to glycine substitution in the second amino acid of the protein.
- the transfer vector used for overexpression of B15R and B18R in vaccinia virus was pRK19 (Kent, R.K. 1988), which contains the vaccinia virus 4b promoter to control the transcription of the inserted gene, flanked by sequences of the TK gene that allow insertion in the TK locus of the virus genome.
- BamHI fragments containing the ORFs were excised from pAA4 and pAA5 and cloned into the BamHI site of pRK19, and the resulting plasmids were named pAA10 and pAA11, respectively.
- the transfer vector for construction of baculovirus recombinants was pAcDZl, which uses the polyhedrin promoter to drive the transcription of foreign genes and coexpresses Escherichia coli ⁇ -galactosidase for
- the genes were excised from pAA4 and ⁇ AA5 with BamHI and inserted into BamHI-cut pAcDZl, forming pAA14 and pAA15, respectively.
- flanking sequences of B15R and B18R were excised from pAA1 or clones from a M13 library containing random subfragments of the SalII fragment of vaccinia DNA, which were used to sequence this region of the vaccinia virus genome (Smith et al, 1991a), and were cloned into pSJH7 (Hughes et al, 1991).
- the 5' flanking region of B15R was obtained by digestion of the replicative form of the M13 clone SalII.144 with EcoRI and SphI, and the 3' flanking region was excised from pAA1 by digestion with SphI and BamHI. Both fragments were, cloned in one step into
- the resultant plasmid contained 360 and 1316 nt of the 5' and 3' flanking sequence, including 17 and 252 nt of the coding sequence, respectively, so that 72% of the B15R coding sequence was deleted.
- DNA fragments containing the flanking sequences of B18R were obtained by BamHI and EcoRI digestion of the replicative form of the M13 clones SalII.44 and SalII.81.
- PCR fragment was obtained with the oligonucleotide B15R-2 (above) and the 17-mer sequencing primer (-20), using pAA1 as template.
- the PCR product was purified, labeled with [ - 32 P]ATP and polynucleotide kinase, and
- pAA2 was digested with EcoRI, a band of 505 bp was purified and dephosphorylated with calf intestinal alkaline
- Both 32 P-labeled fragments specific for B15R and B18R were hybridized to 10 ⁇ g of vaccinia virus RNA obtained at 8 hr after infection from cells infected in the presence (early) or absence (late) of cycloheximide or yeast transfer RNA.
- the hybrids were digested with SI nuclease, and the protected fragments were separated on 6% polyacrylamide sequencing gel and detected by
- Sf cells were cotransfected with purified AcNPV DNA and pAA14 or pAA15 using the calcium phosphate precipitation technique, and the recombinant viruses were identified by staining with X-GaI as described (Zuidema et al, 1990). The insertion of foreign genes (B15R and B18R) into the baculovirus genome was confirmed by
- Recombinant vaccinia viruses were constructed by standard procedures (Mackett et al, 1985). The genomes of viruses containing a second copy of B15R or B18R in the TK locus of the vaccinia DNA were analyzed by
- Vaccinia virus deletion mutants were constructed by transient dominant selection as described elsewhere ( Falkner and Moss, 1990; Isaacs et al, 1990).
- Vaccinia viruses containing deleted versions of B15R and B18R were termed vAA5 and vAA6, respectively, and are referred to here as v B15R and v B18R.
- the B15R-specific probe containing the ORF and 348 bp of the 3' flanking region was excised from pAA4 by digestion with BamHI and used for Southern blot
- the oligonucleotide B15R-2 was used as an internal probe for B15R ORF.
- the internal probe for B18R was obtained by excision of a 424 bp EcoRI fragment from pAA2.
- Biomedicals a mixture of -80% [ 35 S]methionine and -20% [ 35 S] cysteine, 1200 Ci/mmol) in methionine-free TC100 medium or methionine- and cysteine-free minimal essential medium, respectively, in the absence of serum.
- Cytosine arabinoside 40 ⁇ g/ml
- tunicamycin 1 ⁇ g/ml
- Radioactive bands were detected by autoradiography or fluorography with salicilate (Harlow and Lane, 1988).
- Sf cells and TK-143 cells grown in 175 cm 2 or 80 cm 2 flasks, were infected at a density of 1.5 ⁇ 10 5 to 2 ⁇ 10 5 cells/cm 2 with a multiplicity of infection of 5-10 pfu per cell in serum-free medium.
- Cells and medium were harvested from vaccinia- or baculovirus-infected cells at 1 or 3 days after infection, respectively.
- the final concentration of the supematants was 1 ⁇ 10 6 to 5 ⁇ 10 6 cell equivalents per millilitre.
- the medium was
- supematants made 20 mM HEPES (pH 7.4) and 0.1% sodium azide.
- Supematants were stored at -70°C until used in binding assays in solution or concentrated and dialized against phosphate-buffered saline ( PBS ) at 4°C in a Micro-ProDiCon (Bio-Molecular Dynamics) with PA-10 ProDiMen dialysis membranes (MW 10,000) to a-final concentration of 5 ⁇ 10 7 cell equivalents per millilitre.
- the concentrated medium was made 1% in sodium azide and stored at -70°C.
- the supematants were harvested from cells seeded at a cellular density of 5 ⁇ 10 5 cells per
- Sf and TK-143 cells were harvested for binding assays to intact cells by treatment with PBS containing 0.5 mM EDTA.
- EL4 6.1 C10, U266, Sf, and TK-143 cells were washed twice in serum-free medium and resuspended in binding medium.
- the binding medium used in the different assays was RPMI 1640 containing 20 mM HEPES ( pH 704), 1% bovine serum albumin, and 0.1% sodium azide. Solid phase binding assays on nitrocellulose were performed as described (Urdal et al, 1988). Binding to intact cells was carried out in duplicate in 150 ⁇ l of binding medium for 2 hr at 4°C, and bound 125 I-IL was determined by phthlate oil centrifugation as described (Dower et al, 1985). In the competition assays of labeled ILs to intact cells, samples were preincubated with the ILs in 125 ⁇ l for 1 hr at 4°C. Subsequently, 2.5 x 10 6 EL4 6.1 C10 or U266 cells were added in 25 ⁇ l and incubated for 2 hr at 4°C.
- Soluble receptor binding assays were performed by precipitating the ligand-receptor complexes with
- mice Female BALB/c mice ( 5 to 6 weeks old) were anesthetized and infected intranasally with 20 ⁇ l of the diluted virus in 1 mM Tris-HCI ( pH 9.0). Mice were weighed daily and monitored for signs of illness or death (Turner, 1967; Williamson et al, 1990). As a control, an aliquot of the dilutions of v B15R or WR used to inculate the animals was grown in TK-143 cells, and the absence or the presence of IL-1 ⁇ binding activity in the medium at 24 hr after infection was confirmed in a binding assay in solution (data not shown).
- mice 4-6 weeks old BALB/c mice were intranasally infected with doses of WR, v B15R or v B18R as shown in Table 2. The table also shows the mortality of animals after 15 days.
- FIG. 4A shows that the B15R-specific probe was partially protected from SI nuclease digestion by late viral RNA, and the size of the protected fragment mapped the transcriptional start site to the TAAAAT motif at the 5' end of B15R.
- TAAAT(G) has been shown to constitute a late promoter consensus sequence for vaccinia virus, a few exceptions have been found that possess an additional A TMOSS, 1990b).
- the B18R-specific probe was protected from S1 nucflease digestion by early viral RNA that initiated 16-18 nt upstream of the ORF ( Figure 4B).
- Vaccinia virus recombinants overexpressing the proteins or lacking the coding regions were constructed to identify the gene products and to study the biological activity of the proteins. Overexpression of the proteins was achieved by cloning a second copy of B15R or B18R, transcribed under the control of the late 4b promoter, in the thymidine kinase (TK) locus.
- the genomic structure of the recombinant viruses, called vB15R and vB18R was confirmed by Southern blot hybridization ( Figure 5A) and by polymerase chain reaction (PCR) using oligonucleotides specific for the 5' and 3' ends of the TK gene (data not shown).
- cytosine arabinoside were performed in cells infected with different vaccinia virus recombinants.
- Extracts from cells or culture supematants were obtained by:
- the protein encoded by B18R was detected in vaccinia virus-infected cells when overexpressed at late times of infection under the strong 4b promoter but was not detected in the deletion mutant (Figure 6B). Two forms of the protein (52kd and 60-65kd) were detected in cell extracts, and only the 60-65 kd protein, presumably containing a higher degree of glycosylation, was secreted to the medium. Since translation of B18R-specific mRNA in rabbit reticuloyte lysates produces a protein of the predicted size of 40 kd (Ueda et al., 1990), the
- carbohydrate component of the secreted B18R gene product accounts for 33%-38% of the size of the protein.
- expressed in insect cells might not recognise that form of the protein.
- Spodoptera frugiperda insect cells infected with Autographa califomica nuclear polyhedrosis virus (AcNPV) under the control of the polyhedrin promoter.
- AcNPV Autographa califomica nuclear polyhedrosis virus
- the recombinant viruses constructed were termed AcB15R and AcB18R.
- the 45 kd protein in AcB15R-infected insect cell extracts might correspond to a glycosylated form with a signal sequence still bound to the polypeptide, possibly owing to the inability of insect cells to process properly the high amount of B15R protein expressed under the strong
- baculovirus was not detected while these ligands bound to EL46.lC10 and U266 cells, which overexpress IL-1 and IL-6 receptors, respectively.
- IL-1 ⁇ binding activity was clearly found in vaccinia virus-infected cells and supematants harvested at 24 hr after infection and in the baculovirus recombinant expressing B15R 3 days after infection.
- the low binding to EL4 6.1C10 cells at this dose of 125 I-IL-1 ⁇ probably reflects a 6-fold lower affinity for the ⁇ form compared with IL-1 ⁇ , described for the type I receptor expressed in this cell line (Sims et al., 1988).
- IL-1 ⁇ receptor The kinetics of production of soluble IL-1 ⁇ receptor from vaccinia virus-infected cells was examined by soluble binding assay and showed that no IL-1 ⁇ receptor was detected above the background attributable to virus inoculum, in the presence of cytosine arabinoside. In contrast, in the absence of the drug, IL-1 ⁇ accumulated in the supernatant and reached 80% of total by 24 hr (data not shown). These data are consistent with the transcriptional and polypeptide analyses and show that the IL-1 ⁇ receptor is expressed late during infection.
- Figure 8 shows the binding of radioiodinated IL-1 ⁇ to medium from different recombinants using 1 ⁇ 10 4 cell equivalents, conditions that allowed a better
- the natural competitor IL-1RA did not block the binding of labelled IL-1 ⁇ to vaccinia IL-1 receptor, even when added at higher concentrations that are required to compete the binding of 125 I-IL-1 to the type II IL-1 receptor on polymorphonuclear leukocytes or a pre-B lymphocyte line (Dripps et al., 1991; Granowitz et al., 1991; Mclntyre et al., 1991).
- the doses of unlabelled ILs used competed the binding of the corresponding .
- radioiodinated IL to its natural receptor on EL4 6.1 C10 or U266 cells (data not shown).
- the receptor expressed in the baculovirus system showed similar properties.
- equivalents of medium from AcB15R-infected cells was 94.1%, 7.4%, 99.0% and 110.1% in the presence of 10nM of IL-1 ⁇ , 10nM of IL-1 ⁇ , 100nM of IL-1ra, and 10nM of IL-6, respectively.
- K D dissociation constant
- Table 2 and Figure 14 show the results for the in vivo experiment in which mice were intranasally infected with doses of WR, v B15R or v B18R. The results show that groups of mice infected with a vaccinia virus unable to produce the B18R gene product had a lower incidence of mortality than equivalent groups of mice infected with either wild-type vaccinia virus or a vaccinia virus unable to produce the B15R gene product. In Figure 14, mortality and symptoms of illness are presented-as a function of days post-inoculation.
- mice infected with either wild-type vaccinia virus or a vaccinia virus unable to produce the B15R gene product The incidence of mortality was similar for groups of mice infected with either wild-type vaccinia virus or a vaccinia virus unable to produce the B15R gene product. However, symptoms of illness appeared sooner in groups of mice infected with vaccinia virus unable to produce the B15R gene product as compared to equivalent groups of mice infected with the wild-type vaccinia virus.
- the IL-1 ⁇ , IL-1 ⁇ , and IL-6 binding activity was investigated in a soluble receptor binding assay on supematants from cultures infected with different strains of vaccinia virus (Copenhagen, IHD-J, IHD-W, Wyeth, Lister, Tian-Tan, and Tashkent) and the related orthopoxviruses rabbitpox and cowpox compared with the WR strain.
- the binding to labelled murine IL-1 ⁇ (mIL-1 ⁇ ) was also investigated to confirm that B15R is able to sequester IL-1 ⁇ in infected mice. No binding to human 125 I-IL-1 ⁇ or 125 I-IL-6 was detected (data not shown). However, binding to labelled IL-1 ⁇ and mIL-1 ⁇ was found in all viruses except for rabbitpox, Tashkent and
- Copenhagen to express an IL-1 receptor is in agreement with sequencing data that showed a nonsense mutation at codon 31 of the ORF (Goebel et al., 1990). Even if translation reinitiated from the next methionine codon, which seems unlikely given its distance from the mRNA 5' end, the protein would lack a signal peptide and..
- B15R protein is shown to suppress the temperature of the infected mouse over the first six days of infection.
- mice infected with the Tian-Tan strain which expresses the IL-1 ⁇ receptor, have reduced temperatures following infection, while those animals infected with strains lacking the receptor
- ORFs Two vaccinia virus ORFs, B15R and B18R, that encode proteins of the immunoglobulin superfamily related to the extracellular domains of the IL-1 and IL-6 receptors have been characterized. Both ORFs are transcribed, but at different phases of the virus replication cycle,
- the B18R gene product Is shown not to bind IL-1 ⁇ , IL-1 ⁇ or IL-6, despite the homology with the receptors for these cytokines (McMahan et al, 1991; Smith and Chan, 1991). Two forms of the protein (52 kd and 60-65 kd) were detected, the larger of which is found in
- B15R ORF is shown to encode an IL-1 ⁇ binding activity present in the supematants of vaccinia virus-infected cells and to represent a novel soluble IL-1 receptor.
- the high affinity for IL-1 ⁇ binding (K D 234 pM) is similar to those reported for the cellular receptors (Sims et al, 1988, 1989; McMahan et al, 1991) and is consistent with the retention of full binding activity by the extracellular domain of the IL-1 receptor (Dower et al, 1989).
- the size (50-60 kd ) and high carbohydrate content of the mature vaccinia IL-1 ⁇ receptor are in agreement with those reported for the truncated and complete versions of the cellular receptor, respectively (Urdal et al, 1988; Dower et al, 1989).
- the secretion of a biologically active 40-44 kd protein from insect cells suggests that the carbohydrate is not an essential component for the IL-1 binding.
- the vaccinia IL-1 receptor constitutes a novel receptor for IL-1 because of the specificity, for IL-1 ⁇ . This was shown in binding experiments to radioiodinated ILs and was corroborated in competition assays with unlabeled cytokines and by blocking the interaction of the ILs with the natural receptor on cells in culture.
- B15R has a higher similarity to the cellular type II receptor than to the type I receptor (McMahan et al, 1991; Smith and Chan, 1991) and since this similarity is comparable with those found between other vaccinia virus proteins and their cellular counterparts (Smith et al, 1991a), B15R may derive from the type II IL-1 receptor or a variant thereof.
- the comparison of the sequence of the vaccinia IL-1 ⁇ receptor with the type I and type II IL-1 receptors does not permit identification of the amino acids that confer specificity for IL-1 ⁇ since the
- sequences are quite divergent. However, the availability of the vaccinia virus gene will allow mutagenesis studies to identify these positions. Furthermore, the sequence of B15R ORF in other vaccinia virus strains that show different affinities for the human and murine IEr-1 ⁇ may provide structural information on the binding domain. In this case, the comparison of the sequence may be more useful since genes from different orthopoxviruses are highly conserved.
- the vaccinia IL-1 ⁇ receptor might be useful as a tool to investigate the function of IL-1 ⁇ and IL-1 ⁇ in vivo in different models.
- the other IL-1 inhibitors available IL-IRA, a soluble truncated IL-1 receptor, and monoclonal antibodies against the receptor
- IL-IRA a soluble truncated IL-1 receptor
- monoclonal antibodies against the receptor block the binding of both forms of IL-1 (Fanslow et al, 1990; Gershenwald et al, 1990; Ohlsson et al, 1990;
- the molecule may regulate responses normally controlled by IL-1 ⁇ , and, since it does not bind IL-1 ⁇ or IL-1RA, it might offer advantages over the other inhibitors.
- the failure of the vaccinia IL-1 ⁇ receptor to bind IL-1RA illustrates the adaptation of the virus to the physiological response of the host by preventing interference with the natural antagonist.
- the number of IL-1 ⁇ binding sites secreted from vaccinia virus-infected cells is without precedent and makes the supematants from cultures infected with vaccinia virus the most concentrated naturally occurring soluble IL-1 binding activity.
- An excess of soluble receptors must be required to block the effects of IL-1 ⁇ in vivo, since only a few cellular IL-1 receptors need to be occupied to elicit a biological response. This was illustrated in the competition of IL-1 ⁇ binding to T- cells, which also indicates that the vaccinia IL-1 ⁇ receptor will probably block the biological effects induced in cells expressing IL-1 receptors.
- IL-1 ⁇ in the host response to orthopoxvirus infections.
- virulence is defined according to the number of
- vaccinia IL-1 ⁇ receptor does play an important role in vaccinia virus infection in vivo.
- the animals infected with v B15R developed symptoms and lost weight more rapidly than the corresponding control group.
- the early onset of symptoms is very likely to represent systemic effects induced by circulating IL-1 ⁇ produced in response to vaccinia virus infection.
- IL-1 is known to function as a hormone mediating multiple effects such as fever, headache, and sleep and at high doses can induce hypotension and a shocklike state (Dinarello, 1988,
- the vaccinia IL-1 ⁇ receptor expressed in the wild-type virus, may thus limit the systemic acute phase response otherwise initiated by increased levels of IL-1 ⁇ .
- weight loss which can be induced by IL-1 (Di Giovine and Duff, 1990) occurred earlier in animals infected with v B15R supports this view.
- a generalized response can contribute to host defense; for example, temperature typical of fever has been reported to enhance the proliferation of T-cells that might facilitate a T-cell-dependent immune response (Duff and Durum. 1983).
- an increased systemic reaction to infection did not affect the outcome of infection by v B15R. Second, although the absolute number of
- B15R might function as a virulence or attenuation factor for the virus. It is unclear whether the effects of deleting B15R from the WR strain of vaccinia virus, which was selected for high
- B15R ORF is one of a few virus genes that has been shown to increase the pathogenicity or the severity of the infection when deleted from the virus genome
- Virus attenuation can result from deletion or
- IL-1 ⁇ is the predominant form of IL-1 secreted from human monocytes (Hazuda et al, 1988), and the release of adrenocorticotropic hormone, one of the neuroendocrine actions of IL-1, is exclusively induced by IL-1 ⁇ (Uehara et al, 1987).
- IL-1 ⁇ is more potent than IL-1 ⁇ in the induction of fever, and the effect is mediated through different mechanisms (Busbridge et al, 1989), which correlates with the discovery of IL-1 ⁇ (Breder et al, 1988) and receptors specific for IL-1 ⁇ (Katsuura et al, 1988) in the brain.
- B15R is the second soluble cytokine receptor to be identified in a virus.
- a soluble receptor for tumor necrosis factor (TNF) has been shown to be active in Leporipoxviruses and to increase the pathogenicity of the virus (Smith et al, 1991b; Upton et al, 1991).
- the WR and Copenhagen strains of vaccinia virus contain one and two homologs, respectively, of the TNF receptor, but the presence of frameshifts and stop codons make expression of active proteins unlikely (Howard et al, 1991; Upton et al, 1991).
- the soluble IL-1 ⁇ receptor is one of the increasing number of activities encoded by vaccinia virus that aid evasion from the host immune system (for references see Moore and Smith, 1992) and, in particular, is another viral-encoded protein that interferes with cytokine functions.
- the TNF receptor of leporipoxvirus and the crmA protein of cowpox virus other examples found are the 14.7 kd protein of adenovirus that inhibits cytolysis by TNF (Gooding et al, 1988), the IL-10
- the vaccinia IL-1 ⁇ receptor may be a useful tool to discriminate the physiological roles of IL-1 ⁇ and IL-1 ⁇ and might be used as an anti-inflammatory therapeutic reagent.
- the expression of this activity by vaccinia virus and other orthopoxviruses represents a novel mechanism of virus evasion from the immune system. It is shown that the IL-1 ⁇ receptor is modulating the systemic response to infection and the severity of the disease, which suggests that IL-1 ⁇ , and not IL-1 ⁇ , is the main mediator of the endocrine effects of the IL-1 produced in response to vaccinia virus infection in mice.
- Interleukin 1 the first interleukin. Immunol. Today 11, 13-20.
- Blocking IL-1 interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today 12, 404-410.
- Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J. Biol. Chem. 266, 20311-20315.
- Verderber E., Brewer, M.T., Hannum, C.H., and Thompson, R.C. (1990). Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343, 341-346.
- interleukin-1 receptor J.Biol.Chem. 265, 17416-17419.
- Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J. Biol. Chem. 266, 14147-14150.
- Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor is Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343, 336-340.
- Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family are included in the tumor necrosis factor receptor family.
- Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of
- a novel IL-1 receptor cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10, 2821-2832.
- LIGAND a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
- cowpox virus encodes an inhibitor of the interleukin-1 ⁇ converting enzyme.
- T2 open reading frame from Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem.
- Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71, this issue.
- a soluble binding protein specific for interleukin 1 ⁇ is produced by activated mononuclear cells. Cytokine 2, 190-198.
- Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 184, 370-382.
- polyhedrin-based baculovirus expression vector polyhedrin-based baculovirus expression vector.
- CHNCAM 1 4.12 4.01 4.07 3.19 5.54 3.28
- NB 4/5 4 deaths in a group of 5
- mice 4-6 week old Balb/c mice were infected intranasally with indicated doses of WR, B15R-deleted (v ⁇ 15ft) or B188-del (v ⁇ B18F)virus. The mortality of animals after 15 days is show
- Values of greater than 3.1 are significant (probability 10 -3 ), while values of 4.8, 6.0 and 7.9 indicate probabilities of 10 -6 , 10 -9 and 10 -15 , respectively.
- the domains illustrated are from B15R amino acids 28-119 (1), 121-214 (2), 222-end (3): B18R 53-149 (1), 152-241 (2), 252-end (3); murine IL-1R precursor (Sims, J.E., March, C.J., Widmer, M.B., MacDonald, H.R., McMahan, D.J., Grubin, C.E., Wignall, J.M., Jackson, J.L., Call, S.M. Friend, D., Alpert, A.R.
- human IL-6R Yamasaki, K., Taga, T., Hirat, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T and Kishismoto, T. (1988).
- Proc. Jpn. Acad. 64, 209-211 27-116; murine neural cell adhesion molecule L1 precursor (L1CAM) (Moos, M., Tacke, R., Scherer, H., Teplow, D., Freuth, K., Schachner, M. (1988).
- CHNCAM chicken neural cell adhesion molecule
- MAG myelin-associated glycoprotein
- PDGFR platelet derived growth factor receptor
- T cell receptor CD3 epsilon chain (TCRCD3) (Clevers, H., Duiilap, S., Saito, H., Georgopoulos, K., Wileman, T. and Terhorst, C., (1988). Proc. Natl. Acad. Sci. USA 85, 8623-8627) 1-82; leukocyte antigen receptor protein (LAR) (Streuli, M., Krueger, N.X., Hall, L.R., Schlossman, S.F. and Saito, H. (1988). J. Exp. Med.
- LAR leukocyte antigen receptor protein
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36418/93A AU3641893A (en) | 1992-03-05 | 1993-03-05 | Vaccinia virus b15r used in interleukin b1-involving condition |
EP93905517A EP0656949A1 (en) | 1992-03-05 | 1993-03-05 | Vaccinia virus b15r used in interleukin b1-involving condition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929204780A GB9204780D0 (en) | 1992-03-05 | 1992-03-05 | Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods |
GB9204780.2 | 1992-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993018153A1 true WO1993018153A1 (en) | 1993-09-16 |
Family
ID=10711551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/000460 WO1993018153A1 (en) | 1992-03-05 | 1993-03-05 | Vaccinia virus b15r used in interleukin b1-involving condition |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0656949A1 (en) |
GB (1) | GB9204780D0 (en) |
WO (1) | WO1993018153A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014622A2 (en) * | 2003-08-07 | 2005-02-17 | F. Hoffmann-La Roche Ag | Ra antigenic peptides |
WO2005030971A1 (en) * | 2003-09-29 | 2005-04-07 | Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh | Modified vaccinia virus ankara (mva) mutant and use thereof |
WO2020011754A1 (en) * | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007944A1 (en) * | 1990-10-26 | 1992-05-14 | Lynxvale Limited | Vaccinia vectors, vaccinia genes and expression products thereof |
-
1992
- 1992-03-05 GB GB929204780A patent/GB9204780D0/en active Pending
-
1993
- 1993-03-05 WO PCT/GB1993/000460 patent/WO1993018153A1/en not_active Application Discontinuation
- 1993-03-05 EP EP93905517A patent/EP0656949A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007944A1 (en) * | 1990-10-26 | 1992-05-14 | Lynxvale Limited | Vaccinia vectors, vaccinia genes and expression products thereof |
Non-Patent Citations (2)
Title |
---|
CELL vol. 71, no. 1, October 1992, CAMBRIDGE, NA US pages 153 - 167 ALCAMI, A. ET SMITH, G.L. 'A soluble receptor for interleukin-1-beta encoded by vaccinia virus a novel mechnism of virus modulation of the host response to infection' * |
JOURNAL OF GENERAL VIROLOGY vol. 72, no. 3, March 1991, GB pages 511 - 518 SMITH, G.L. ET CHAN, Y. S. 'Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily' cited in the application * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014622A2 (en) * | 2003-08-07 | 2005-02-17 | F. Hoffmann-La Roche Ag | Ra antigenic peptides |
WO2005014622A3 (en) * | 2003-08-07 | 2005-05-06 | Hoffmann La Roche | Ra antigenic peptides |
KR100769338B1 (en) * | 2003-08-07 | 2007-10-24 | 에프. 호프만-라 로슈 아게 | Ra antigenic peptides |
WO2005030971A1 (en) * | 2003-09-29 | 2005-04-07 | Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh | Modified vaccinia virus ankara (mva) mutant and use thereof |
US7767209B2 (en) | 2003-09-29 | 2010-08-03 | Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
CN1842602B (en) * | 2003-09-29 | 2011-06-29 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | Modified vaccinia virus ankara (MVA) mutant and use thereof |
WO2020011754A1 (en) * | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
Also Published As
Publication number | Publication date |
---|---|
GB9204780D0 (en) | 1992-04-15 |
EP0656949A1 (en) | 1995-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alcami et al. | A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection | |
Upton et al. | Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence | |
Massung et al. | Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975 | |
US6998252B1 (en) | Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences | |
Whitford et al. | Identification and sequence analysis of a gene encoding gp67, an abundant envelope glycoprotein of the baculovirus Autographa californica nuclear polyhedrosis virus | |
Guo et al. | Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals | |
Duncan et al. | Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress | |
US7384643B2 (en) | Recombinant poxvirus | |
AU595190B2 (en) | A transcriptional regulatory sequence from the 5'flanking region of the vaccinia virus | |
Kettle et al. | Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model | |
US5420026A (en) | Self-assembling replication defective hybrid virus particles | |
Takahashi-Nishimaki et al. | Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins | |
Barry et al. | The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes | |
PT752888E (en) | Nucleotide and amino acid sequences of canine herpesvirus gb, gc and gd and uses therefor | |
JP2007082551A (en) | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] composition and use thereof | |
WO1992007944A1 (en) | Vaccinia vectors, vaccinia genes and expression products thereof | |
US5476781A (en) | Entomopoxvirus spheroidin gene sequences | |
WO1990012101A1 (en) | Vaccinia vectors, vaccinia genes and expression products thereof | |
Rodriguez et al. | Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells | |
Smith et al. | Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences | |
Gong et al. | A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus | |
Calvert et al. | Identification and functional analysis of the fowlpox virus homolog of the vaccinia virus p37K major envelope antigen gene | |
WO1993018153A1 (en) | Vaccinia virus b15r used in interleukin b1-involving condition | |
Strayer et al. | Sequence and analysis of a portion of the genomes of Shope fibroma virus and malignant rabbit fibroma virus that is important for viral replication in lymphocytes | |
US6933145B1 (en) | Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993905517 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1994 295707 Date of ref document: 19941107 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1993905517 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993905517 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |